GSK•benzinga•
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Summary
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga